{"generated":"2026-10-30","inputs":{"factcheck":"2026-10-26","trialChanges":"2026-10-26","fda":"2026-10-28","regional":"2026-10-28"},"proposals":[{"kind":"regulatory-event","confidence":"high","entityId":"enzalutamide","entityName":"Enzalutamide","entityKind":"drug","route":"/drugs/enzalutamide/","file":"src/data/interactions.ts","line":112,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/interactions.ts#L112","field":"regulatoryEvents","current":"0 events; none dated 2026-10-26","proposed":"{ date: \"2026-10-26\", type: \"approval\", region: \"US\", note: \"approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive\" }","evidence":"On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) g","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive","detected":"2026-10-28","id":"regulatory-event:enzalutamide:regulatoryevents:-date:-2026-10-26-type:-approval-region:-us-note:-approves-talazoparib-with-enzalutamide-for-metastatic-androgen-"},{"kind":"regulatory-event","confidence":"high","entityId":"talazoparib","entityName":"Talazoparib","entityKind":"drug","route":"/drugs/talazoparib/","file":"src/data/checkpoint-map.ts","line":612,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/checkpoint-map.ts#L612","field":"regulatoryEvents","current":"2 events; none dated 2026-10-26","proposed":"{ date: \"2026-10-26\", type: \"approval\", region: \"US\", note: \"approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive\" }","evidence":"On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) g","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive","detected":"2026-10-28","id":"regulatory-event:talazoparib:regulatoryevents:-date:-2026-10-26-type:-approval-region:-us-note:-approves-talazoparib-with-enzalutamide-for-metastatic-androgen-p"},{"kind":"regulatory-event","confidence":"high","entityId":"pembrolizumab","entityName":"Pembrolizumab","entityKind":"drug","route":"/drugs/pembrolizumab/","file":"src/data/checkpoint-map.ts","line":158,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/checkpoint-map.ts#L158","field":"regulatoryEvents","current":"49 events; none dated 2026-10-16","proposed":"{ date: \"2026-10-16\", type: \"approval\", region: \"US\", note: \"grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph\" }","evidence":"On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mut","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph","detected":"2026-10-28","id":"regulatory-event:pembrolizumab:regulatoryevents:-date:-2026-10-16-type:-approval-region:-us-note:-grants-traditional-approval-for-pembrolizumab-or-pembrolizumab"},{"kind":"trial-results","confidence":"high","entityId":"keynote-522","entityName":"KEYNOTE-522","entityKind":"trial","route":"/trials/keynote-522/","file":"src/data/regimens.ts","line":154,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/regimens.ts#L154","field":"result / outcomes","current":"EFS HR 0.63; OS HR 0.66 (5-year); 7-year OS 85.1% vs 77.2%.","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT03036488 (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT03036488?tab=results","detected":"2026-10-26","id":"trial-results:keynote-522:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"nct04661007","entityName":"To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL","entityKind":"trial","route":"/trials/nct04661007/","file":"src/data/pipeline-trials-wave5.ts","line":2985,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2985","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT04661007 (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT04661007?tab=results","detected":"2026-10-26","id":"trial-results:nct04661007:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"verify","entityName":"VERIFY","entityKind":"trial","route":"/trials/verify/","file":"src/data/polycythaemia-vera.ts","line":114,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/polycythaemia-vera.ts#L114","field":"result / outcomes","current":"Response (no phlebotomy eligibility) weeks 20 to 32: 77% vs 33%.","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05210790 (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT05210790?tab=results","detected":"2026-10-26","id":"trial-results:verify:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"regulatory-event","confidence":"high","entityId":"dostarlimab","entityName":"Dostarlimab","entityKind":"drug","route":"/drugs/dostarlimab/","file":"src/data/checkpoint-map.ts","line":158,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/checkpoint-map.ts#L158","field":"regulatoryEvents","current":"6 events; none dated 2026-10-19","proposed":"{ date: \"2026-10-19\", type: \"approval\", region: \"US\", note: \"grants accelerated approval to dostarlimab for locally advanced rectal cancer (accelerated)\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer\" }","evidence":"On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer","detected":"2026-10-21","id":"regulatory-event:dostarlimab:regulatoryevents:-date:-2026-10-19-type:-approval-region:-us-note:-grants-accelerated-approval-to-dostarlimab-for-locally-advanced-"},{"kind":"regulatory-event","confidence":"high","entityId":"nogapendekin-alfa","entityName":"Nogapendekin alfa inbakicept","entityKind":"drug","route":"/drugs/nogapendekin-alfa/","file":"src/data/spikes/urothelial.ts","line":138,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/urothelial.ts#L138","field":"regulatoryEvents","current":"0 events; none dated 2026-10-14","proposed":"{ date: \"2026-10-14\", type: \"approval\", region: \"US\", note: \"approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle\" }","evidence":"On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (N","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-expanded-indication-nogapendekin-alfa-inbakicept-pmln-bcg-unresponsive-non-muscle","detected":"2026-10-21","id":"regulatory-event:nogapendekin-alfa:regulatoryevents:-date:-2026-10-14-type:-approval-region:-us-note:-approves-an-expanded-indication-for-nogapendekin-alfa-inba"},{"kind":"regulatory-event","confidence":"high","entityId":"atezolizumab","entityName":"Atezolizumab","entityKind":"drug","route":"/drugs/atezolizumab/","file":"src/data/checkpoint-map.ts","line":252,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/checkpoint-map.ts#L252","field":"regulatoryEvents","current":"15 events; none dated 2026-10-08","proposed":"{ date: \"2026-10-08\", type: \"approval\", region: \"US\", note: \"approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer\" }","evidence":"On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon c","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer","detected":"2026-10-21","id":"regulatory-event:atezolizumab:regulatoryevents:-date:-2026-10-08-type:-approval-region:-us-note:-approves-atezolizumab-in-combination-with-chemotherapy-for-stag"},{"kind":"regulatory-event","confidence":"high","entityId":"trastuzumab","entityName":"Trastuzumab","entityKind":"drug","route":"/drugs/trastuzumab/","file":"src/data/drugs.ts","line":705,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs.ts#L705","field":"regulatoryEvents","current":"7 events; none dated 2026-10-07","proposed":"{ date: \"2026-10-07\", type: \"approval\", region: \"US\", note: \"approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer\" }","evidence":"On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following inductio","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer","detected":"2026-10-21","id":"regulatory-event:trastuzumab:regulatoryevents:-date:-2026-10-07-type:-approval-region:-us-note:-approves-tucatinib-with-trastuzumab-and-pertuzumab-for-the-maint"},{"kind":"regulatory-event","confidence":"high","entityId":"pertuzumab","entityName":"Pertuzumab","entityKind":"drug","route":"/drugs/pertuzumab/","file":"src/data/spikes/breast-her2-positive.ts","line":168,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/breast-her2-positive.ts#L168","field":"regulatoryEvents","current":"5 events; none dated 2026-10-07","proposed":"{ date: \"2026-10-07\", type: \"approval\", region: \"US\", note: \"approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer\" }","evidence":"On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following inductio","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer","detected":"2026-10-21","id":"regulatory-event:pertuzumab:regulatoryevents:-date:-2026-10-07-type:-approval-region:-us-note:-approves-tucatinib-with-trastuzumab-and-pertuzumab-for-the-mainte"},{"kind":"regulatory-event","confidence":"high","entityId":"tucatinib","entityName":"Tucatinib","entityKind":"drug","route":"/drugs/tucatinib/","file":"src/data/drugs.ts","line":713,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs.ts#L713","field":"regulatoryEvents","current":"2 events; none dated 2026-10-07","proposed":"{ date: \"2026-10-07\", type: \"approval\", region: \"US\", note: \"approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer\" }","evidence":"On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following inductio","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-trastuzumab-and-pertuzumab-maintenance-treatment-her2-positive-breast-cancer","detected":"2026-10-21","id":"regulatory-event:tucatinib:regulatoryevents:-date:-2026-10-07-type:-approval-region:-us-note:-approves-tucatinib-with-trastuzumab-and-pertuzumab-for-the-mainten"},{"kind":"trial-results","confidence":"high","entityId":"nct03709680","entityName":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","entityKind":"trial","route":"/trials/nct03709680/","file":"src/data/pipeline-trials-wave5.ts","line":1415,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1415","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT03709680 (detected 2026-10-12).","sourceUrl":"https://clinicaltrials.gov/study/NCT03709680?tab=results","detected":"2026-10-12","id":"trial-results:nct03709680:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"regulatory-event","confidence":"high","entityId":"pirtobrutinib","entityName":"Pirtobrutinib","entityKind":"drug","route":"/drugs/pirtobrutinib/","file":"src/data/interactions.ts","line":120,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/interactions.ts#L120","field":"regulatoryEvents","current":"4 events; none dated 2026-10-02","proposed":"{ date: \"2026-10-02\", type: \"approval\", region: \"US\", note: \"approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma\", source: \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic\" }","evidence":"On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.","sourceUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pirtobrutinib-previously-untreated-chronic-lymphocytic-leukemia-or-small-lymphocytic","detected":"2026-10-07","id":"regulatory-event:pirtobrutinib:regulatoryevents:-date:-2026-10-02-type:-approval-region:-us-note:-approves-pirtobrutinib-for-previously-untreated-chronic-lympho"},{"kind":"trial-results","confidence":"high","entityId":"imvigor011","entityName":"IMvigor011","entityKind":"trial","route":"/trials/imvigor011/","file":"src/data/spikes/lung-trial-sponsors.ts","line":60,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-trial-sponsors.ts#L60","field":"result / outcomes","current":"DFS HR 0.64; OS HR 0.59 in ctDNA+.","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT04660344 (detected 2026-10-05).","sourceUrl":"https://clinicaltrials.gov/study/NCT04660344?tab=results","detected":"2026-10-05","id":"trial-results:imvigor011:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"her2climb-05","entityName":"HER2CLIMB-05","entityKind":"trial","route":"/trials/her2climb-05/","file":"src/data/spikes/breast-her2-positive.ts","line":108,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/breast-her2-positive.ts#L108","field":"result / outcomes","current":"PFS 24.9 vs 16.3 months, HR 0.64.","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05132582 (detected 2026-10-05).","sourceUrl":"https://clinicaltrials.gov/study/NCT05132582?tab=results","detected":"2026-10-05","id":"trial-results:her2climb-05:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"nct06206837","entityName":"A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.","entityKind":"trial","route":"/trials/nct06206837/","file":"src/data/pipeline-trials-wave6.ts","line":1013,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1013","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT06206837 (detected 2026-10-05).","sourceUrl":"https://clinicaltrials.gov/study/NCT06206837?tab=results","detected":"2026-10-05","id":"trial-results:nct06206837:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"nct06331299","entityName":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","entityKind":"trial","route":"/trials/nct06331299/","file":"src/data/pipeline-trials-wave2.ts","line":1083,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L1083","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT06331299 (detected 2026-10-05).","sourceUrl":"https://clinicaltrials.gov/study/NCT06331299?tab=results","detected":"2026-10-05","id":"trial-results:nct06331299:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"nct05023980","entityName":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","entityKind":"trial","route":"/trials/nct05023980/","file":"src/data/pipeline-trials-wave6.ts","line":3580,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L3580","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05023980 (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT05023980?tab=results","detected":"2026-09-28","id":"trial-results:nct05023980:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"rosella","entityName":"ROSELLA / GOG-3073","entityKind":"trial","route":"/trials/rosella/","file":"src/data/spikes/ovarian.ts","line":110,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/ovarian.ts#L110","field":"result / outcomes","current":"OS 16.0 vs 11.9 months (HR 0.69).","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05257408 (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT05257408?tab=results","detected":"2026-09-28","id":"trial-results:rosella:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-results","confidence":"high","entityId":"nct05471843","entityName":"Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma","entityKind":"trial","route":"/trials/nct05471843/","file":"src/data/pipeline-trials-wave5.ts","line":1547,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1547","field":"result / outcomes","current":"(none)","proposed":"add the posted primary outcome with the registry as source","evidence":"ClinicalTrials.gov now has posted results for NCT05471843 (detected 2026-09-28).","sourceUrl":"https://clinicaltrials.gov/study/NCT05471843?tab=results","detected":"2026-09-28","id":"trial-results:nct05471843:result-outcomes:add-the-posted-primary-outcome-with-the-registry-as-source"},{"kind":"trial-status","confidence":"medium","entityId":"nct07428044","entityName":"A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct07428044/","file":"src/data/spikes/lung-registry-trials.ts","line":1442,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L1442","field":"status","current":"recruiting","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is WITHDRAWN; recorded recruiting. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07428044","id":"trial-status:nct07428044:status:withdrawn","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"nct05879822","entityName":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","entityKind":"trial","route":"/trials/nct05879822/","file":"src/data/pipeline-trials-wave6.ts","line":8807,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L8807","field":"status","current":"active","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded active. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT05879822","id":"trial-status:nct05879822:status:withdrawn","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"clocc","entityName":"CLOCC","entityKind":"trial","route":"/trials/clocc/","file":"src/data/spikes/colorectal-treatment-trials-advanced.ts","line":218,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-treatment-trials-advanced.ts#L218","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT00043004","id":"trial-status:clocc:status:withdrawn","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"cyto-pv","entityName":"CYTO-PV","entityKind":"trial","route":"/trials/cyto-pv/","file":"src/data/polycythaemia-vera.ts","line":70,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/polycythaemia-vera.ts#L70","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT01645124","id":"trial-status:cyto-pv:status:withdrawn","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"destiny-lung01","entityName":"DESTINY-Lung01","entityKind":"trial","route":"/trials/destiny-lung01/","file":"src/data/trials-subtypes-wave.ts","line":46,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/trials-subtypes-wave.ts#L46","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03505710","id":"trial-status:destiny-lung01:status:withdrawn","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"nct05358249","entityName":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","entityKind":"trial","route":"/trials/nct05358249/","file":"src/data/pipeline-trials-wave5.ts","line":3429,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3429","field":"status","current":"active","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded active. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT05358249","id":"trial-status:nct05358249:status:withdrawn","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"rockstar","entityName":"ROCKstar","entityKind":"trial","route":"/trials/rockstar/","file":"src/data/issues-2026-09-wave-a.ts","line":124,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/issues-2026-09-wave-a.ts#L124","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03640481","id":"trial-status:rockstar:status:withdrawn","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"tower","entityName":"TOWER","entityKind":"trial","route":"/trials/tower/","file":"src/data/spikes/all-leukemia.ts","line":115,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/all-leukemia.ts#L115","field":"status","current":"positive","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT02013167","id":"trial-status:tower:status:withdrawn","detected":"2026-10-30"},{"kind":"drug-approval","confidence":"medium","entityId":"aspirin","entityName":"Aspirin","entityKind":"drug","route":"/drugs/aspirin/","file":"src/data/essential-thrombocythaemia.ts","line":76,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/essential-thrombocythaemia.ts#L76","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Aspirin\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:aspirin:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-30"},{"kind":"drug-approval","confidence":"medium","entityId":"danazol","entityName":"Danazol","entityKind":"drug","route":"/drugs/danazol/","file":"src/data/drugs-subtypes-wave.ts","line":247,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-subtypes-wave.ts#L247","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Danazol\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:danazol:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-30"},{"kind":"drug-approval","confidence":"medium","entityId":"givinostat","entityName":"Givinostat","entityKind":"drug","route":"/drugs/givinostat/","file":"src/data/drugs-pipeline-wave1.ts","line":553,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-pipeline-wave1.ts#L553","field":"approvals / status","current":"status phase-3; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Givinostat\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:givinostat:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-30"},{"kind":"drug-approval","confidence":"medium","entityId":"ivermectin","entityName":"Ivermectin","entityKind":"drug","route":"/drugs/ivermectin/","file":"src/data/ivermectin.ts","line":65,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/ivermectin.ts#L65","field":"approvals / status","current":"status phase-2; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Ivermectin\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:ivermectin:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-30"},{"kind":"drug-approval","confidence":"medium","entityId":"metyrapone","entityName":"Metyrapone","entityKind":"drug","route":"/drugs/metyrapone/","file":"src/data/drugs-subtypes-wave.ts","line":161,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-subtypes-wave.ts#L161","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Metyrapone\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:metyrapone:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-30"},{"kind":"drug-approval","confidence":"medium","entityId":"mifepristone","entityName":"Mifepristone","entityKind":"drug","route":"/drugs/mifepristone/","file":"src/data/drugs-subtypes-wave.ts","line":101,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/drugs-subtypes-wave.ts#L101","field":"approvals / status","current":"status negative; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Mifepristone\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:mifepristone:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-30"},{"kind":"drug-approval","confidence":"medium","entityId":"pancrelipase","entityName":"Pancrelipase (pancreatic enzyme replacement therapy)","entityKind":"drug","route":"/drugs/pancrelipase/","file":"src/data/spikes/pancreatic-treatment.ts","line":59,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-treatment.ts#L59","field":"approvals / status","current":"status established; no US approval recorded","proposed":"add { region: \"US\", year: <from label>, indication: <from label> } and set status to approved","evidence":"openFDA has a label for \"Pancrelipase\"","sourceUrl":"https://open.fda.gov/apis/drug/label/","id":"drug-approval:pancrelipase:approvals-status:add-region:-us-year:-from-label-indication:-from-label-and-set-status-to-approved","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"nct06295432","entityName":"A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)","entityKind":"trial","route":"/trials/nct06295432/","file":"src/data/pipeline-trials-wave5.ts","line":3315,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3315","field":"status","current":"recruiting","proposed":"completed","evidence":"ClinicalTrials.gov overall status is COMPLETED; recorded recruiting. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT06295432","id":"trial-status:nct06295432:status:completed","detected":"2026-10-30"},{"kind":"regional-row","confidence":"medium","entityId":"daraxonrasib","entityName":"Daraxonrasib","entityKind":"drug","route":"/drugs/daraxonrasib/","file":"src/data/regional-approvals.ts","field":"EU","current":"(no EU entry)","proposed":"EU entry from the register page (Opinion)","evidence":"EMA register: Rasonque (Daraxonrasib) Opinion. Register page: \"Opinion: EMA has issued an opinion on this medicine\", opinion Positive 2026-10-15.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/rasonque","reason":"CHMP opinion (Positive) without a Commission decision yet; the row would change again within weeks","id":"regional-row:daraxonrasib:eu:eu-entry-from-the-register-page-opinion-","detected":"2026-10-30"},{"kind":"trial-status","confidence":"medium","entityId":"ratify","entityName":"RATIFY (CALGB 10603)","entityKind":"trial","route":"/trials/ratify/","file":"src/data/spikes/aml.ts","line":281,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/aml.ts#L281","field":"status","current":"positive","proposed":"completed","evidence":"Registry status moved from UNKNOWN to COMPLETED (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT00651261","detected":"2026-10-26","id":"trial-status:ratify:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"a071401","entityName":"Alliance A071401","entityKind":"trial","route":"/trials/a071401/","file":"src/data/issues-2026-09-wave-b.ts","line":239,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/issues-2026-09-wave-b.ts#L239","field":"yearReported / calendar","current":"2027-01-01","proposed":"2028-06-01","evidence":"Primary completion date moved from 2027-01-01 to 2028-06-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT02523014","detected":"2026-10-26","id":"trial-completion:a071401:yearreported-calendar:2028-06-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct03150693","entityName":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","entityKind":"trial","route":"/trials/nct03150693/","file":"src/data/spikes/trial-sponsor-companies.ts","line":200,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/trial-sponsor-companies.ts#L200","field":"yearReported / calendar","current":"2027-03-01","proposed":"2027-11-01","evidence":"Primary completion date moved from 2027-03-01 to 2027-11-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT03150693","detected":"2026-10-26","id":"trial-completion:nct03150693:yearreported-calendar:2027-11-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct03491683","entityName":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","entityKind":"trial","route":"/trials/nct03491683/","file":"src/data/pipeline-trials-wave6.ts","line":9542,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L9542","field":"yearReported / calendar","current":"2026-12-31","proposed":"2027-12-31","evidence":"Primary completion date moved from 2026-12-31 to 2027-12-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT03491683","detected":"2026-10-26","id":"trial-completion:nct03491683:yearreported-calendar:2027-12-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct03711032","entityName":"Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)","entityKind":"trial","route":"/trials/nct03711032/","file":"src/data/pipeline-trials-wave6.ts","line":7796,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7796","field":"yearReported / calendar","current":"2026-07-31","proposed":"2028-07-31","evidence":"Primary completion date moved from 2026-07-31 to 2028-07-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT03711032","detected":"2026-10-26","id":"trial-completion:nct03711032:yearreported-calendar:2028-07-31"},{"kind":"trial-status","confidence":"medium","entityId":"nct04129502","entityName":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","entityKind":"trial","route":"/trials/nct04129502/","file":"src/data/pipeline-trials-wave4.ts","line":1104,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1104","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT04129502","detected":"2026-10-26","id":"trial-status:nct04129502:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04129502","entityName":"TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","entityKind":"trial","route":"/trials/nct04129502/","file":"src/data/pipeline-trials-wave4.ts","line":1104,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1104","field":"yearReported / calendar","current":"2026-10-31","proposed":"2026-09-22","evidence":"Primary completion date moved from 2026-10-31 to 2026-09-22; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04129502","detected":"2026-10-26","id":"trial-completion:nct04129502:yearreported-calendar:2026-09-22"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04267848","entityName":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Ch","entityKind":"trial","route":"/trials/nct04267848/","file":"src/data/spikes/lung-registry-trials.ts","line":1562,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L1562","field":"yearReported / calendar","current":"2027-01-31","proposed":"2030-01-31","evidence":"Primary completion date moved from 2027-01-31 to 2030-01-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04267848","detected":"2026-10-26","id":"trial-completion:nct04267848:yearreported-calendar:2030-01-31"},{"kind":"trial-status","confidence":"medium","entityId":"nct04557449","entityName":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","entityKind":"trial","route":"/trials/nct04557449/","file":"src/data/pipeline-trials-wave5.ts","line":2495,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2495","field":"status","current":"active","proposed":"recruiting","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT04557449","detected":"2026-10-26","id":"trial-status:nct04557449:status:recruiting"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04557449","entityName":"Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors","entityKind":"trial","route":"/trials/nct04557449/","file":"src/data/pipeline-trials-wave5.ts","line":2495,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2495","field":"yearReported / calendar","current":"2026-09-23","proposed":"2029-10-07","evidence":"Primary completion date moved from 2026-09-23 to 2029-10-07; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04557449","detected":"2026-10-26","id":"trial-completion:nct04557449:yearreported-calendar:2029-10-07"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04606446","entityName":"Study of PF-07248144 in Advanced or Metastatic Solid Tumors","entityKind":"trial","route":"/trials/nct04606446/","file":"src/data/pipeline-trials-wave5.ts","line":2859,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2859","field":"yearReported / calendar","current":"2029-07-13","proposed":"2029-08-27","evidence":"Primary completion date moved from 2029-07-13 to 2029-08-27; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04606446","detected":"2026-10-26","id":"trial-completion:nct04606446:yearreported-calendar:2029-08-27"},{"kind":"trial-status","confidence":"medium","entityId":"magnetismm-3","entityName":"MagnetisMM-3","entityKind":"trial","route":"/trials/magnetismm-3/","file":"src/data/spikes/lung-trial-sponsors.ts","line":94,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-trial-sponsors.ts#L94","field":"status","current":"positive","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT04649359","detected":"2026-10-26","id":"trial-status:magnetismm-3:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04736173","entityName":"Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer","entityKind":"trial","route":"/trials/nct04736173/","file":"src/data/pipeline-trials-wave5.ts","line":2310,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2310","field":"yearReported / calendar","current":"2027-05","proposed":"2026-09-17","evidence":"Primary completion date moved from 2027-05 to 2026-09-17; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04736173","detected":"2026-10-26","id":"trial-completion:nct04736173:yearreported-calendar:2026-09-17"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05294731","entityName":"Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader","entityKind":"trial","route":"/trials/nct05294731/","file":"src/data/pipeline-trials-wave5.ts","line":3621,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3621","field":"yearReported / calendar","current":"2029-01-31","proposed":"2027-06-30","evidence":"Primary completion date moved from 2029-01-31 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05294731","detected":"2026-10-26","id":"trial-completion:nct05294731:yearreported-calendar:2027-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05358249","entityName":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","entityKind":"trial","route":"/trials/nct05358249/","file":"src/data/pipeline-trials-wave5.ts","line":3429,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3429","field":"yearReported / calendar","current":"2026-09-30","proposed":"2026-09-28","evidence":"Primary completion date moved from 2026-09-30 to 2026-09-28; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05358249","detected":"2026-10-26","id":"trial-completion:nct05358249:yearreported-calendar:2026-09-28"},{"kind":"trial-completion","confidence":"medium","entityId":"combomatch-binimetinib-folfox","entityName":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations","entityKind":"trial","route":"/trials/combomatch-binimetinib-folfox/","file":"src/data/spikes/gallbladder-treatment.ts","line":372,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/gallbladder-treatment.ts#L372","field":"yearReported / calendar","current":"2026-10-01","proposed":"2026-08-08","evidence":"Primary completion date moved from 2026-10-01 to 2026-08-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05564403","detected":"2026-10-26","id":"trial-completion:combomatch-binimetinib-folfox:yearreported-calendar:2026-08-08"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05585320","entityName":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","entityKind":"trial","route":"/trials/nct05585320/","file":"src/data/pipeline-trials-wave5.ts","line":1761,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1761","field":"yearReported / calendar","current":"2026-06","proposed":"2027-06","evidence":"Primary completion date moved from 2026-06 to 2027-06; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05585320","detected":"2026-10-26","id":"trial-completion:nct05585320:yearreported-calendar:2027-06"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05605535","entityName":"Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer","entityKind":"trial","route":"/trials/nct05605535/","file":"src/data/pipeline-trials-wave5.ts","line":1230,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1230","field":"yearReported / calendar","current":"2026-10-15","proposed":"2027-05-15","evidence":"Primary completion date moved from 2026-10-15 to 2027-05-15; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05605535","detected":"2026-10-26","id":"trial-completion:nct05605535:yearreported-calendar:2027-05-15"},{"kind":"trial-status","confidence":"medium","entityId":"nct05827081","entityName":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","entityKind":"trial","route":"/trials/nct05827081/","file":"src/data/pipeline-trials-wave6.ts","line":8729,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L8729","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT05827081","detected":"2026-10-26","id":"trial-status:nct05827081:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05934331","entityName":"A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study","entityKind":"trial","route":"/trials/nct05934331/","file":"src/data/pipeline-trials-wave6.ts","line":4216,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L4216","field":"yearReported / calendar","current":"2026-07-01","proposed":"2031-08-06","evidence":"Primary completion date moved from 2026-07-01 to 2031-08-06; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05934331","detected":"2026-10-26","id":"trial-completion:nct05934331:yearreported-calendar:2031-08-06"},{"kind":"trial-status","confidence":"medium","entityId":"nct05957367","entityName":"A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies","entityKind":"trial","route":"/trials/nct05957367/","file":"src/data/pipeline-trials-wave6.ts","line":6078,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6078","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT05957367","detected":"2026-10-26","id":"trial-status:nct05957367:status:active"},{"kind":"trial-status","confidence":"medium","entityId":"nct06188520","entityName":"A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With ","entityKind":"trial","route":"/trials/nct06188520/","file":"src/data/pipeline-trials-wave5.ts","line":102,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L102","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT06188520","detected":"2026-10-26","id":"trial-status:nct06188520:status:active"},{"kind":"trial-status","confidence":"medium","entityId":"nct06279364","entityName":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","entityKind":"trial","route":"/trials/nct06279364/","file":"src/data/pipeline-trials-wave6.ts","line":6840,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6840","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT06279364","detected":"2026-10-26","id":"trial-status:nct06279364:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06279364","entityName":"A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer","entityKind":"trial","route":"/trials/nct06279364/","file":"src/data/pipeline-trials-wave6.ts","line":6840,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6840","field":"yearReported / calendar","current":"2026-07","proposed":"2027-04","evidence":"Primary completion date moved from 2026-07 to 2027-04; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06279364","detected":"2026-10-26","id":"trial-completion:nct06279364:yearreported-calendar:2027-04"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06283719","entityName":"Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P","entityKind":"trial","route":"/trials/nct06283719/","file":"src/data/pipeline-trials-wave5.ts","line":1499,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1499","field":"yearReported / calendar","current":"2026-04","proposed":"2027-04","evidence":"Primary completion date moved from 2026-04 to 2027-04; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06283719","detected":"2026-10-26","id":"trial-completion:nct06283719:yearreported-calendar:2027-04"},{"kind":"trial-status","confidence":"medium","entityId":"nct06331299","entityName":"A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer","entityKind":"trial","route":"/trials/nct06331299/","file":"src/data/pipeline-trials-wave2.ts","line":1083,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L1083","field":"status","current":"active","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT06331299","detected":"2026-10-26","id":"trial-status:nct06331299:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06356311","entityName":"A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)","entityKind":"trial","route":"/trials/nct06356311/","file":"src/data/pipeline-trials-wave4.ts","line":724,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L724","field":"yearReported / calendar","current":"2027-01-04","proposed":"2026-10-19","evidence":"Primary completion date moved from 2027-01-04 to 2026-10-19; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06356311","detected":"2026-10-26","id":"trial-completion:nct06356311:yearreported-calendar:2026-10-19"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06499285","entityName":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular B","entityKind":"trial","route":"/trials/nct06499285/","file":"src/data/pipeline-trials-wave3.ts","line":132,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave3.ts#L132","field":"yearReported / calendar","current":"2028-05-01","proposed":"2028-09-15","evidence":"Primary completion date moved from 2028-05-01 to 2028-09-15; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06499285","detected":"2026-10-26","id":"trial-completion:nct06499285:yearreported-calendar:2028-09-15"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06510374","entityName":"Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer","entityKind":"trial","route":"/trials/nct06510374/","file":"src/data/pipeline-trials-wave6.ts","line":4198,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L4198","field":"yearReported / calendar","current":"2028-06-30","proposed":"2028-09-30","evidence":"Primary completion date moved from 2028-06-30 to 2028-09-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06510374","detected":"2026-10-26","id":"trial-completion:nct06510374:yearreported-calendar:2028-09-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06616532","entityName":"PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct06616532/","file":"src/data/pipeline-trials-wave2.ts","line":97,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L97","field":"yearReported / calendar","current":"2027-01-25","proposed":"2027-05","evidence":"Primary completion date moved from 2027-01-25 to 2027-05; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06616532","detected":"2026-10-26","id":"trial-completion:nct06616532:yearreported-calendar:2027-05"},{"kind":"trial-status","confidence":"medium","entityId":"nct06623136","entityName":"A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct06623136/","file":"src/data/pipeline-trials-wave5.ts","line":3913,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3913","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT06623136","detected":"2026-10-26","id":"trial-status:nct06623136:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06686394","entityName":"Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)","entityKind":"trial","route":"/trials/nct06686394/","file":"src/data/pipeline-trials-wave6.ts","line":5334,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5334","field":"yearReported / calendar","current":"2030-04-18","proposed":"2032-08-02","evidence":"Primary completion date moved from 2030-04-18 to 2032-08-02; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06686394","detected":"2026-10-26","id":"trial-completion:nct06686394:yearreported-calendar:2032-08-02"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06702995","entityName":"Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","entityKind":"trial","route":"/trials/nct06702995/","file":"src/data/pipeline-trials-wave5.ts","line":3781,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3781","field":"yearReported / calendar","current":"2026-05-13","proposed":"2027-07-13","evidence":"Primary completion date moved from 2026-05-13 to 2027-07-13; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06702995","detected":"2026-10-26","id":"trial-completion:nct06702995:yearreported-calendar:2027-07-13"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06841159","entityName":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Can","entityKind":"trial","route":"/trials/nct06841159/","file":"src/data/spikes/colorectal-registry-trials.ts","line":3641,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L3641","field":"yearReported / calendar","current":"2026-03-01","proposed":"2029-09-30","evidence":"Primary completion date moved from 2026-03-01 to 2029-09-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06841159","detected":"2026-10-26","id":"trial-completion:nct06841159:yearreported-calendar:2029-09-30"},{"kind":"trial-status","confidence":"medium","entityId":"nct06857175","entityName":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)","entityKind":"trial","route":"/trials/nct06857175/","file":"src/data/pipeline-trials-wave6.ts","line":3372,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L3372","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT06857175","detected":"2026-10-26","id":"trial-status:nct06857175:status:active"},{"kind":"trial-status","confidence":"medium","entityId":"nct07052214","entityName":"PSMA PET Combined With MRI for the Detection of PCa","entityKind":"trial","route":"/trials/nct07052214/","file":"src/data/pipeline-trials-wave4.ts","line":1472,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1472","field":"status","current":"recruiting","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT07052214","detected":"2026-10-26","id":"trial-status:nct07052214:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07222488","entityName":"A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)","entityKind":"trial","route":"/trials/nct07222488/","file":"src/data/pipeline-trials-wave6.ts","line":8077,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L8077","field":"yearReported / calendar","current":"2029-02-28","proposed":"2027-07-30","evidence":"Primary completion date moved from 2029-02-28 to 2027-07-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07222488","detected":"2026-10-26","id":"trial-completion:nct07222488:yearreported-calendar:2027-07-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07254585","entityName":"SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma","entityKind":"trial","route":"/trials/nct07254585/","file":"src/data/pipeline-trials-wave5.ts","line":3195,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3195","field":"yearReported / calendar","current":"2026-06-30","proposed":"2028-06-30","evidence":"Primary completion date moved from 2026-06-30 to 2028-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07254585","detected":"2026-10-26","id":"trial-completion:nct07254585:yearreported-calendar:2028-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07416058","entityName":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","entityKind":"trial","route":"/trials/nct07416058/","file":"src/data/spikes/lung-registry-trials.ts","line":433,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L433","field":"yearReported / calendar","current":"2027-12-31","proposed":"2027-12-30","evidence":"Primary completion date moved from 2027-12-31 to 2027-12-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07416058","detected":"2026-10-26","id":"trial-completion:nct07416058:yearreported-calendar:2027-12-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07499362","entityName":"Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)","entityKind":"trial","route":"/trials/nct07499362/","file":"src/data/pipeline-trials-wave6.ts","line":7289,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7289","field":"yearReported / calendar","current":"2029-11-22","proposed":"2028-08-22","evidence":"Primary completion date moved from 2029-11-22 to 2028-08-22; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07499362","detected":"2026-10-26","id":"trial-completion:nct07499362:yearreported-calendar:2028-08-22"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07595874","entityName":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","entityKind":"trial","route":"/trials/nct07595874/","file":"src/data/spikes/colorectal-registry-trials.ts","line":1446,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L1446","field":"yearReported / calendar","current":"2027-05-27","proposed":"2028-12-16","evidence":"Primary completion date moved from 2027-05-27 to 2028-12-16; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07595874","detected":"2026-10-26","id":"trial-completion:nct07595874:yearreported-calendar:2028-12-16"},{"kind":"trial-status","confidence":"medium","entityId":"nct07824882","entityName":"A Phase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20093 Injection in Previously Treated Patients With Advanced or Metastatic Non-Squamo","entityKind":"trial","route":"/trials/nct07824882/","file":"src/data/spikes/lung-registry-trials.ts","line":999,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L999","field":"status","current":"planned","proposed":"recruiting","evidence":"Registry status moved from NOT_YET_RECRUITING to RECRUITING (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT07824882","detected":"2026-10-26","id":"trial-status:nct07824882:status:recruiting"},{"kind":"trial-completion","confidence":"medium","entityId":"nct03816163","entityName":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","entityKind":"trial","route":"/trials/nct03816163/","file":"src/data/pipeline-trials-wave6.ts","line":2117,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2117","field":"yearReported / calendar","current":"2026-08-31","proposed":"2026-10-31","evidence":"Primary completion date moved from 2026-08-31 to 2026-10-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT03816163","detected":"2026-10-19","id":"trial-completion:nct03816163:yearreported-calendar:2026-10-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05317858","entityName":"Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets","entityKind":"trial","route":"/trials/nct05317858/","file":"src/data/pipeline-trials-wave4.ts","line":1044,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1044","field":"yearReported / calendar","current":"2027-06-01","proposed":"2031-06-01","evidence":"Primary completion date moved from 2027-06-01 to 2031-06-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05317858","detected":"2026-10-19","id":"trial-completion:nct05317858:yearreported-calendar:2031-06-01"},{"kind":"trial-completion","confidence":"medium","entityId":"tropion-breast03","entityName":"TROPION-Breast03","entityKind":"trial","route":"/trials/tropion-breast03/","file":"src/data/pipeline-trials.ts","line":30,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials.ts#L30","field":"yearReported / calendar","current":"2027-09-20","proposed":"2027-09-01","evidence":"Primary completion date moved from 2027-09-20 to 2027-09-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05629585","detected":"2026-10-19","id":"trial-completion:tropion-breast03:yearreported-calendar:2027-09-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06137118","entityName":"AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia","entityKind":"trial","route":"/trials/nct06137118/","file":"src/data/pipeline-trials-wave6.ts","line":7426,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7426","field":"yearReported / calendar","current":"2028-02-11","proposed":"2028-01-06","evidence":"Primary completion date moved from 2028-02-11 to 2028-01-06; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06137118","detected":"2026-10-19","id":"trial-completion:nct06137118:yearreported-calendar:2028-01-06"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06373406","entityName":"A Study of MHB036C for Advanced Solid Tumor","entityKind":"trial","route":"/trials/nct06373406/","file":"src/data/pipeline-trials-wave6.ts","line":79,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L79","field":"yearReported / calendar","current":"2025-12","proposed":"2027-04","evidence":"Primary completion date moved from 2025-12 to 2027-04; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06373406","detected":"2026-10-19","id":"trial-completion:nct06373406:yearreported-calendar:2027-04"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06417814","entityName":"A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participan","entityKind":"trial","route":"/trials/nct06417814/","file":"src/data/pipeline-trials-wave4.ts","line":746,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L746","field":"yearReported / calendar","current":"2026-09-30","proposed":"2027-01-11","evidence":"Primary completion date moved from 2026-09-30 to 2027-01-11; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06417814","detected":"2026-10-19","id":"trial-completion:nct06417814:yearreported-calendar:2027-01-11"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06439771","entityName":"A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC","entityKind":"trial","route":"/trials/nct06439771/","file":"src/data/pipeline-trials-wave6.ts","line":6378,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6378","field":"yearReported / calendar","current":"2026-07-30","proposed":"2027-07-30","evidence":"Primary completion date moved from 2026-07-30 to 2027-07-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06439771","detected":"2026-10-19","id":"trial-completion:nct06439771:yearreported-calendar:2027-07-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06498479","entityName":"ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct06498479/","file":"src/data/pipeline-trials-wave2.ts","line":181,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L181","field":"yearReported / calendar","current":"2026-09-30","proposed":"2026-08-20","evidence":"Primary completion date moved from 2026-09-30 to 2026-08-20; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06498479","detected":"2026-10-19","id":"trial-completion:nct06498479:yearreported-calendar:2026-08-20"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06646276","entityName":"A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS)","entityKind":"trial","route":"/trials/nct06646276/","file":"src/data/pipeline-trials-wave2.ts","line":1191,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L1191","field":"yearReported / calendar","current":"2028-04-06","proposed":"2027-08-17","evidence":"Primary completion date moved from 2028-04-06 to 2027-08-17; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06646276","detected":"2026-10-19","id":"trial-completion:nct06646276:yearreported-calendar:2027-08-17"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06712355","entityName":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","entityKind":"trial","route":"/trials/nct06712355/","file":"src/data/pipeline-trials-wave4.ts","line":84,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L84","field":"yearReported / calendar","current":"2028-12","proposed":"2029-04","evidence":"Primary completion date moved from 2028-12 to 2029-04; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06712355","detected":"2026-10-19","id":"trial-completion:nct06712355:yearreported-calendar:2029-04"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06764186","entityName":"A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain","entityKind":"trial","route":"/trials/nct06764186/","file":"src/data/pipeline-trials-wave6.ts","line":8089,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L8089","field":"yearReported / calendar","current":"2027-12-31","proposed":"2027-11-30","evidence":"Primary completion date moved from 2027-12-31 to 2027-11-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06764186","detected":"2026-10-19","id":"trial-completion:nct06764186:yearreported-calendar:2027-11-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06935409","entityName":"Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure","entityKind":"trial","route":"/trials/nct06935409/","file":"src/data/pipeline-trials-wave2.ts","line":175,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L175","field":"yearReported / calendar","current":"2026-08-31","proposed":"2026-06-17","evidence":"Primary completion date moved from 2026-08-31 to 2026-06-17; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06935409","detected":"2026-10-19","id":"trial-completion:nct06935409:yearreported-calendar:2026-06-17"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07109219","entityName":"Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia","entityKind":"trial","route":"/trials/nct07109219/","file":"src/data/pipeline-trials-wave6.ts","line":4776,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L4776","field":"yearReported / calendar","current":"2028-04-28","proposed":"2028-10-11","evidence":"Primary completion date moved from 2028-04-28 to 2028-10-11; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07109219","detected":"2026-10-19","id":"trial-completion:nct07109219:yearreported-calendar:2028-10-11"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07202364","entityName":"A Study of YL202 in Patients With Advanced Solid Tumors","entityKind":"trial","route":"/trials/nct07202364/","file":"src/data/pipeline-trials-wave5.ts","line":2919,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2919","field":"yearReported / calendar","current":"2026-08-31","proposed":"2027-01-31","evidence":"Primary completion date moved from 2026-08-31 to 2027-01-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07202364","detected":"2026-10-19","id":"trial-completion:nct07202364:yearreported-calendar:2027-01-31"},{"kind":"trial-completion","confidence":"medium","entityId":"symbiotic-gi-16","entityName":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","entityKind":"trial","route":"/trials/symbiotic-gi-16/","file":"src/data/pipeline-trials-wave2.ts","line":19,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L19","field":"yearReported / calendar","current":"2032-01-15","proposed":"2031-07-22","evidence":"Primary completion date moved from 2032-01-15 to 2031-07-22; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07392892","detected":"2026-10-19","id":"trial-completion:symbiotic-gi-16:yearreported-calendar:2031-07-22"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07711002","entityName":"Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)","entityKind":"trial","route":"/trials/nct07711002/","file":"src/data/trials.ts","line":1,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/trials.ts#L1","field":"yearReported / calendar","current":"2031-06-17","proposed":"2031-05-30","evidence":"Primary completion date moved from 2031-06-17 to 2031-05-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07711002","detected":"2026-10-19","id":"trial-completion:nct07711002:yearreported-calendar:2031-05-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct03328078","entityName":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","entityKind":"trial","route":"/trials/nct03328078/","file":"src/data/pipeline-trials-wave6.ts","line":6114,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6114","field":"yearReported / calendar","current":"2026-08","proposed":"2027-07","evidence":"Primary completion date moved from 2026-08 to 2027-07; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT03328078","detected":"2026-10-12","id":"trial-completion:nct03328078:yearreported-calendar:2027-07"},{"kind":"trial-status","confidence":"medium","entityId":"destiny-breast03","entityName":"DESTINY-Breast03","entityKind":"trial","route":"/trials/destiny-breast03/","file":"src/data/spikes/trial-sponsor-companies.ts","line":76,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/trial-sponsor-companies.ts#L76","field":"status","current":"positive","proposed":"completed","evidence":"Registry status moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-10-12).","sourceUrl":"https://clinicaltrials.gov/study/NCT03529110","detected":"2026-10-12","id":"trial-status:destiny-breast03:status:completed"},{"kind":"trial-completion","confidence":"medium","entityId":"nct03678025","entityName":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","entityKind":"trial","route":"/trials/nct03678025/","file":"src/data/spikes/trial-sponsor-companies.ts","line":206,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/trial-sponsor-companies.ts#L206","field":"yearReported / calendar","current":"2028-04-01","proposed":"2033-04-01","evidence":"Primary completion date moved from 2028-04-01 to 2033-04-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT03678025","detected":"2026-10-12","id":"trial-completion:nct03678025:yearreported-calendar:2033-04-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04152499","entityName":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","entityKind":"trial","route":"/trials/nct04152499/","file":"src/data/pipeline-trials-wave5.ts","line":240,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L240","field":"yearReported / calendar","current":"2026-12-31","proposed":"2025-11-30","evidence":"Primary completion date moved from 2026-12-31 to 2025-11-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04152499","detected":"2026-10-12","id":"trial-completion:nct04152499:yearreported-calendar:2025-11-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05006716","entityName":"A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies","entityKind":"trial","route":"/trials/nct05006716/","file":"src/data/pipeline-trials-wave5.ts","line":2728,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2728","field":"yearReported / calendar","current":"2026-11","proposed":"2027-03","evidence":"Primary completion date moved from 2026-11 to 2027-03; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05006716","detected":"2026-10-12","id":"trial-completion:nct05006716:yearreported-calendar:2027-03"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05423262","entityName":"A Study of TRK-950 in Patients With Advanced Solid Tumors","entityKind":"trial","route":"/trials/nct05423262/","file":"src/data/pipeline-trials-wave5.ts","line":552,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L552","field":"yearReported / calendar","current":"2027-12","proposed":"2028-03-31","evidence":"Primary completion date moved from 2027-12 to 2028-03-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05423262","detected":"2026-10-12","id":"trial-completion:nct05423262:yearreported-calendar:2028-03-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05588648","entityName":"Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma","entityKind":"trial","route":"/trials/nct05588648/","file":"src/data/pipeline-trials-wave6.ts","line":8405,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L8405","field":"yearReported / calendar","current":"2025-09","proposed":"2027-12","evidence":"Primary completion date moved from 2025-09 to 2027-12; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05588648","detected":"2026-10-12","id":"trial-completion:nct05588648:yearreported-calendar:2027-12"},{"kind":"trial-status","confidence":"medium","entityId":"harmoni-3","entityName":"HARMONi-3","entityKind":"trial","route":"/trials/harmoni-3/","file":"src/data/spikes/nsclc.ts","line":73,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/nsclc.ts#L73","field":"status","current":"mixed","proposed":"active","evidence":"Registry status moved from RECRUITING to ACTIVE_NOT_RECRUITING (detected 2026-10-12).","sourceUrl":"https://clinicaltrials.gov/study/NCT05899608","detected":"2026-10-12","id":"trial-status:harmoni-3:status:active"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06035497","entityName":"A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)","entityKind":"trial","route":"/trials/nct06035497/","file":"src/data/pipeline-trials-wave6.ts","line":1545,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1545","field":"yearReported / calendar","current":"2027-01-30","proposed":"2026-08-11","evidence":"Primary completion date moved from 2027-01-30 to 2026-08-11; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06035497","detected":"2026-10-12","id":"trial-completion:nct06035497:yearreported-calendar:2026-08-11"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06038578","entityName":"A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer","entityKind":"trial","route":"/trials/nct06038578/","file":"src/data/pipeline-trials-wave6.ts","line":1993,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1993","field":"yearReported / calendar","current":"2026-06-30","proposed":"2027-10-31","evidence":"Primary completion date moved from 2026-06-30 to 2027-10-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06038578","detected":"2026-10-12","id":"trial-completion:nct06038578:yearreported-calendar:2027-10-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06345729","entityName":"A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)","entityKind":"trial","route":"/trials/nct06345729/","file":"src/data/pipeline-trials-wave2.ts","line":199,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L199","field":"yearReported / calendar","current":"2029-02-19","proposed":"2028-01-24","evidence":"Primary completion date moved from 2029-02-19 to 2028-01-24; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06345729","detected":"2026-10-12","id":"trial-completion:nct06345729:yearreported-calendar:2028-01-24"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06498986","entityName":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct06498986/","file":"src/data/pipeline-trials-wave5.ts","line":78,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L78","field":"yearReported / calendar","current":"2026-08","proposed":"2027-06","evidence":"Primary completion date moved from 2026-08 to 2027-06; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06498986","detected":"2026-10-12","id":"trial-completion:nct06498986:yearreported-calendar:2027-06"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06550141","entityName":"Emapalumab Prevention of CAR-T Cell Associated Toxicities","entityKind":"trial","route":"/trials/nct06550141/","file":"src/data/trials-entities-wave5.ts","line":83,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/trials-entities-wave5.ts#L83","field":"yearReported / calendar","current":"2026-08-01","proposed":"2027-08-01","evidence":"Primary completion date moved from 2026-08-01 to 2027-08-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06550141","detected":"2026-10-12","id":"trial-completion:nct06550141:yearreported-calendar:2027-08-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06745323","entityName":"A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC","entityKind":"trial","route":"/trials/nct06745323/","file":"src/data/pipeline-trials-wave5.ts","line":3829,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3829","field":"yearReported / calendar","current":"2029-05-10","proposed":"2029-08-10","evidence":"Primary completion date moved from 2029-05-10 to 2029-08-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06745323","detected":"2026-10-12","id":"trial-completion:nct06745323:yearreported-calendar:2029-08-10"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06780137","entityName":"A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensiv","entityKind":"trial","route":"/trials/nct06780137/","file":"src/data/pipeline-trials-wave5.ts","line":468,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L468","field":"yearReported / calendar","current":"2029-04-27","proposed":"2029-02-15","evidence":"Primary completion date moved from 2029-04-27 to 2029-02-15; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06780137","detected":"2026-10-12","id":"trial-completion:nct06780137:yearreported-calendar:2029-02-15"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06863272","entityName":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","entityKind":"trial","route":"/trials/nct06863272/","file":"src/data/pipeline-trials-wave6.ts","line":4246,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L4246","field":"yearReported / calendar","current":"2031-04-01","proposed":"2031-10-01","evidence":"Primary completion date moved from 2031-04-01 to 2031-10-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06863272","detected":"2026-10-12","id":"trial-completion:nct06863272:yearreported-calendar:2031-10-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07005102","entityName":"A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct07005102/","file":"src/data/pipeline-trials-wave2.ts","line":133,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L133","field":"yearReported / calendar","current":"2031-12","proposed":"2036-11","evidence":"Primary completion date moved from 2031-12 to 2036-11; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07005102","detected":"2026-10-12","id":"trial-completion:nct07005102:yearreported-calendar:2036-11"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07134088","entityName":"A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia","entityKind":"trial","route":"/trials/nct07134088/","file":"src/data/pipeline-trials-wave6.ts","line":4902,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L4902","field":"yearReported / calendar","current":"2028-12-05","proposed":"2031-03-06","evidence":"Primary completion date moved from 2028-12-05 to 2031-03-06; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07134088","detected":"2026-10-12","id":"trial-completion:nct07134088:yearreported-calendar:2031-03-06"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07821684","entityName":"A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanc","entityKind":"trial","route":"/trials/nct07821684/","file":"src/data/spikes/lung-registry-trials.ts","line":770,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L770","field":"yearReported / calendar","current":"2031-04","proposed":"2030-03","evidence":"Primary completion date moved from 2031-04 to 2030-03; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07821684","detected":"2026-10-12","id":"trial-completion:nct07821684:yearreported-calendar:2030-03"},{"kind":"trial-completion","confidence":"medium","entityId":"nci-match","entityName":"NCI-MATCH (EAY131)","entityKind":"trial","route":"/trials/nci-match/","file":"src/data/platform-trials-wave.ts","line":90,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/platform-trials-wave.ts#L90","field":"yearReported / calendar","current":"2026-12-31","proposed":"2027-12-31","evidence":"Primary completion date moved from 2026-12-31 to 2027-12-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT02465060","detected":"2026-10-05","id":"trial-completion:nci-match:yearreported-calendar:2027-12-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04396821","entityName":"A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors","entityKind":"trial","route":"/trials/nct04396821/","file":"src/data/pipeline-trials-wave5.ts","line":1457,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1457","field":"yearReported / calendar","current":"2026-05-30","proposed":"2027-06-30","evidence":"Primary completion date moved from 2026-05-30 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04396821","detected":"2026-10-05","id":"trial-completion:nct04396821:yearreported-calendar:2027-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04415853","entityName":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","entityKind":"trial","route":"/trials/nct04415853/","file":"src/data/pipeline-trials-wave2.ts","line":1065,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L1065","field":"yearReported / calendar","current":"2026-08","proposed":"2027-08","evidence":"Primary completion date moved from 2026-08 to 2027-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04415853","detected":"2026-10-05","id":"trial-completion:nct04415853:yearreported-calendar:2027-08"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04495296","entityName":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","entityKind":"trial","route":"/trials/nct04495296/","file":"src/data/pipeline-trials-wave5.ts","line":3639,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3639","field":"yearReported / calendar","current":"2026-06-25","proposed":"2027-06-30","evidence":"Primary completion date moved from 2026-06-25 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04495296","detected":"2026-10-05","id":"trial-completion:nct04495296:yearreported-calendar:2027-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04711252","entityName":"A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease","entityKind":"trial","route":"/trials/nct04711252/","file":"src/data/pipeline-trials-wave6.ts","line":5154,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5154","field":"yearReported / calendar","current":"2026-08-24","proposed":"2026-06-26","evidence":"Primary completion date moved from 2026-08-24 to 2026-06-26; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04711252","detected":"2026-10-05","id":"trial-completion:nct04711252:yearreported-calendar:2026-06-26"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04980222","entityName":"A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma","entityKind":"trial","route":"/trials/nct04980222/","file":"src/data/pipeline-trials-wave6.ts","line":7163,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7163","field":"yearReported / calendar","current":"2024-09-24","proposed":"2024-10-24","evidence":"Primary completion date moved from 2024-09-24 to 2024-10-24; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04980222","detected":"2026-10-05","id":"trial-completion:nct04980222:yearreported-calendar:2024-10-24"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05296798","entityName":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","entityKind":"trial","route":"/trials/nct05296798/","file":"src/data/pipeline-trials-wave6.ts","line":1409,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1409","field":"yearReported / calendar","current":"2027-10-31","proposed":"2028-06-15","evidence":"Primary completion date moved from 2027-10-31 to 2028-06-15; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05296798","detected":"2026-10-05","id":"trial-completion:nct05296798:yearreported-calendar:2028-06-15"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05731271","entityName":"A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors","entityKind":"trial","route":"/trials/nct05731271/","file":"src/data/pipeline-trials-wave6.ts","line":2039,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2039","field":"yearReported / calendar","current":"2026-06","proposed":"2027-06-30","evidence":"Primary completion date moved from 2026-06 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05731271","detected":"2026-10-05","id":"trial-completion:nct05731271:yearreported-calendar:2027-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05932212","entityName":"AK104 for Recurrent or Metastatic Vulvar Cancer","entityKind":"trial","route":"/trials/nct05932212/","file":"src/data/pipeline-trials-wave5.ts","line":684,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L684","field":"yearReported / calendar","current":"2025-12-15","proposed":"2026-05-31","evidence":"Primary completion date moved from 2025-12-15 to 2026-05-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05932212","detected":"2026-10-05","id":"trial-completion:nct05932212:yearreported-calendar:2026-05-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06125522","entityName":"TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)","entityKind":"trial","route":"/trials/nct06125522/","file":"src/data/pipeline-trials-wave6.ts","line":761,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L761","field":"yearReported / calendar","current":"2026-12-31","proposed":"2026-09-10","evidence":"Primary completion date moved from 2026-12-31 to 2026-09-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06125522","detected":"2026-10-05","id":"trial-completion:nct06125522:yearreported-calendar:2026-09-10"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06362252","entityName":"A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-","entityKind":"trial","route":"/trials/nct06362252/","file":"src/data/pipeline-trials-wave5.ts","line":3189,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3189","field":"yearReported / calendar","current":"2026-09-30","proposed":"2027-07-20","evidence":"Primary completion date moved from 2026-09-30 to 2027-07-20; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06362252","detected":"2026-10-05","id":"trial-completion:nct06362252:yearreported-calendar:2027-07-20"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06619236","entityName":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","entityKind":"trial","route":"/trials/nct06619236/","file":"src/data/pipeline-trials-wave4.ts","line":1448,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1448","field":"yearReported / calendar","current":"2027-02","proposed":"2026-08-18","evidence":"Primary completion date moved from 2027-02 to 2026-08-18; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06619236","detected":"2026-10-05","id":"trial-completion:nct06619236:yearreported-calendar:2026-08-18"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07024173","entityName":"A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","entityKind":"trial","route":"/trials/nct07024173/","file":"src/data/pipeline-trials-wave2.ts","line":301,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L301","field":"yearReported / calendar","current":"2026-12","proposed":"2027-08","evidence":"Primary completion date moved from 2026-12 to 2027-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07024173","detected":"2026-10-05","id":"trial-completion:nct07024173:yearreported-calendar:2027-08"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07143604","entityName":"A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2","entityKind":"trial","route":"/trials/nct07143604/","file":"src/data/pipeline-trials-wave6.ts","line":827,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L827","field":"yearReported / calendar","current":"2026-09-28","proposed":"2026-08-14","evidence":"Primary completion date moved from 2026-09-28 to 2026-08-14; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07143604","detected":"2026-10-05","id":"trial-completion:nct07143604:yearreported-calendar:2026-08-14"},{"kind":"trial-completion","confidence":"medium","entityId":"symbiotic-gi-03","entityName":"Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer","entityKind":"trial","route":"/trials/symbiotic-gi-03/","file":"src/data/pipeline-trials-wave2.ts","line":13,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L13","field":"yearReported / calendar","current":"2030-03-29","proposed":"2030-02-23","evidence":"Primary completion date moved from 2030-03-29 to 2030-02-23; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07222800","detected":"2026-10-05","id":"trial-completion:symbiotic-gi-03:yearreported-calendar:2030-02-23"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07288203","entityName":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","entityKind":"trial","route":"/trials/nct07288203/","file":"src/data/pipeline-trials-wave5.ts","line":1677,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1677","field":"yearReported / calendar","current":"2032-12","proposed":"2027-12","evidence":"Primary completion date moved from 2032-12 to 2027-12; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07288203","detected":"2026-10-05","id":"trial-completion:nct07288203:yearreported-calendar:2027-12"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07336446","entityName":"A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs","entityKind":"trial","route":"/trials/nct07336446/","file":"src/data/pipeline-trials-wave5.ts","line":2388,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2388","field":"yearReported / calendar","current":"2029-01-26","proposed":"2026-11-05","evidence":"Primary completion date moved from 2029-01-26 to 2026-11-05; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07336446","detected":"2026-10-05","id":"trial-completion:nct07336446:yearreported-calendar:2026-11-05"},{"kind":"trial-completion","confidence":"medium","entityId":"symbiotic-gi-16","entityName":"Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer","entityKind":"trial","route":"/trials/symbiotic-gi-16/","file":"src/data/pipeline-trials-wave2.ts","line":19,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L19","field":"yearReported / calendar","current":"2031-07-22","proposed":"2032-01-15","evidence":"Primary completion date moved from 2031-07-22 to 2032-01-15; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07392892","detected":"2026-10-05","id":"trial-completion:symbiotic-gi-16:yearreported-calendar:2032-01-15"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07421700","entityName":"Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer","entityKind":"trial","route":"/trials/nct07421700/","file":"src/data/pipeline-trials-wave6.ts","line":3664,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L3664","field":"yearReported / calendar","current":"2027-12-06","proposed":"2027-12-28","evidence":"Primary completion date moved from 2027-12-06 to 2027-12-28; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07421700","detected":"2026-10-05","id":"trial-completion:nct07421700:yearreported-calendar:2027-12-28"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07473128","entityName":"Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct07473128/","file":"src/data/pipeline-trials-wave4.ts","line":1080,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1080","field":"yearReported / calendar","current":"2027-06","proposed":"2027-10-31","evidence":"Primary completion date moved from 2027-06 to 2027-10-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07473128","detected":"2026-10-05","id":"trial-completion:nct07473128:yearreported-calendar:2027-10-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07476287","entityName":"Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed","entityKind":"trial","route":"/trials/nct07476287/","file":"src/data/pipeline-trials-wave5.ts","line":1421,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1421","field":"yearReported / calendar","current":"2028-03-19","proposed":"2028-03-24","evidence":"Primary completion date moved from 2028-03-19 to 2028-03-24; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07476287","detected":"2026-10-05","id":"trial-completion:nct07476287:yearreported-calendar:2028-03-24"},{"kind":"trial-completion","confidence":"medium","entityId":"nct02650401","entityName":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","entityKind":"trial","route":"/trials/nct02650401/","file":"src/data/pipeline-trials-wave6.ts","line":5136,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5136","field":"yearReported / calendar","current":"2026-06-30","proposed":"2027-06-30","evidence":"Primary completion date moved from 2026-06-30 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT02650401","detected":"2026-09-28","id":"trial-completion:nct02650401:yearreported-calendar:2027-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04590326","entityName":"A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamata","entityKind":"trial","route":"/trials/nct04590326/","file":"src/data/pipeline-trials-wave5.ts","line":636,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L636","field":"yearReported / calendar","current":"2027-03-25","proposed":"2028-11-08","evidence":"Primary completion date moved from 2027-03-25 to 2028-11-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04590326","detected":"2026-09-28","id":"trial-completion:nct04590326:yearreported-calendar:2028-11-08"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04626479","entityName":"Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)","entityKind":"trial","route":"/trials/nct04626479/","file":"src/data/pipeline-trials-wave6.ts","line":2207,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2207","field":"yearReported / calendar","current":"2026-08-21","proposed":"2026-08-10","evidence":"Primary completion date moved from 2026-08-21 to 2026-08-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04626479","detected":"2026-09-28","id":"trial-completion:nct04626479:yearreported-calendar:2026-08-10"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04626518","entityName":"Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)","entityKind":"trial","route":"/trials/nct04626518/","file":"src/data/pipeline-trials-wave6.ts","line":5780,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5780","field":"yearReported / calendar","current":"2026-08-21","proposed":"2026-07-23","evidence":"Primary completion date moved from 2026-08-21 to 2026-07-23; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04626518","detected":"2026-09-28","id":"trial-completion:nct04626518:yearreported-calendar:2026-07-23"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04662255","entityName":"Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)","entityKind":"trial","route":"/trials/nct04662255/","file":"src/data/pipeline-trials-wave6.ts","line":7772,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7772","field":"yearReported / calendar","current":"2027-01","proposed":"2027-11","evidence":"Primary completion date moved from 2027-01 to 2027-11; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04662255","detected":"2026-09-28","id":"trial-completion:nct04662255:yearreported-calendar:2027-11"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04924075","entityName":"Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL","entityKind":"trial","route":"/trials/nct04924075/","file":"src/data/pipeline-trials-wave5.ts","line":1862,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1862","field":"yearReported / calendar","current":"2029-12-27","proposed":"2032-11-18","evidence":"Primary completion date moved from 2029-12-27 to 2032-11-18; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04924075","detected":"2026-09-28","id":"trial-completion:nct04924075:yearreported-calendar:2032-11-18"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04925479","entityName":"Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia","entityKind":"trial","route":"/trials/nct04925479/","file":"src/data/pipeline-trials-wave6.ts","line":3568,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L3568","field":"yearReported / calendar","current":"2027-09-21","proposed":"2027-09-02","evidence":"Primary completion date moved from 2027-09-21 to 2027-09-02; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04925479","detected":"2026-09-28","id":"trial-completion:nct04925479:yearreported-calendar:2027-09-02"},{"kind":"trial-completion","confidence":"medium","entityId":"majestec-3","entityName":"MajesTEC-3","entityKind":"trial","route":"/trials/majestec-3/","file":"src/data/spikes/multiple-myeloma.ts","line":205,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/multiple-myeloma.ts#L205","field":"yearReported / calendar","current":"2025-09-15","proposed":"2025-08-01","evidence":"Primary completion date moved from 2025-09-15 to 2025-08-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05083169","detected":"2026-09-28","id":"trial-completion:majestec-3:yearreported-calendar:2025-08-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05132075","entityName":"Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer","entityKind":"trial","route":"/trials/nct05132075/","file":"src/data/pipeline-trials-wave2.ts","line":373,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L373","field":"yearReported / calendar","current":"2026-08-25","proposed":"2026-09-03","evidence":"Primary completion date moved from 2026-08-25 to 2026-09-03; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05132075","detected":"2026-09-28","id":"trial-completion:nct05132075:yearreported-calendar:2026-09-03"},{"kind":"trial-completion","confidence":"medium","entityId":"herizon-gea-01","entityName":"HERIZON-GEA-01","entityKind":"trial","route":"/trials/herizon-gea-01/","file":"src/data/spikes/gastric.ts","line":80,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/gastric.ts#L80","field":"yearReported / calendar","current":"2026-09-30","proposed":"2026-07-15","evidence":"Primary completion date moved from 2026-09-30 to 2026-07-15; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05152147","detected":"2026-09-28","id":"trial-completion:herizon-gea-01:yearreported-calendar:2026-07-15"},{"kind":"trial-completion","confidence":"medium","entityId":"rosella","entityName":"ROSELLA / GOG-3073","entityKind":"trial","route":"/trials/rosella/","file":"src/data/spikes/ovarian.ts","line":110,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/ovarian.ts#L110","field":"yearReported / calendar","current":"2025-03-24","proposed":"2025-03-31","evidence":"Primary completion date moved from 2025-03-24 to 2025-03-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05257408","detected":"2026-09-28","id":"trial-completion:rosella:yearreported-calendar:2025-03-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05528133","entityName":"Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer","entityKind":"trial","route":"/trials/nct05528133/","file":"src/data/spikes/tnbc-registry-trials.ts","line":993,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/tnbc-registry-trials.ts#L993","field":"yearReported / calendar","current":"2028-05","proposed":"2029-09","evidence":"Primary completion date moved from 2028-05 to 2029-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05528133","detected":"2026-09-28","id":"trial-completion:nct05528133:yearreported-calendar:2029-09"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05552976","entityName":"A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W","entityKind":"trial","route":"/trials/nct05552976/","file":"src/data/pipeline-trials-wave4.ts","line":1466,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L1466","field":"yearReported / calendar","current":"2026-07-18","proposed":"2026-09-28","evidence":"Primary completion date moved from 2026-07-18 to 2026-09-28; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05552976","detected":"2026-09-28","id":"trial-completion:nct05552976:yearreported-calendar:2026-09-28"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05745740","entityName":"A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation","entityKind":"trial","route":"/trials/nct05745740/","file":"src/data/spikes/lung-registry-trials.ts","line":716,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L716","field":"yearReported / calendar","current":"2025-12","proposed":"2027-12-01","evidence":"Primary completion date moved from 2025-12 to 2027-12-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05745740","detected":"2026-09-28","id":"trial-completion:nct05745740:yearreported-calendar:2027-12-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05752136","entityName":"Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma","entityKind":"trial","route":"/trials/nct05752136/","file":"src/data/spikes/colorectal-registry-trials.ts","line":3119,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L3119","field":"yearReported / calendar","current":"2025-04","proposed":"2026-11-01","evidence":"Primary completion date moved from 2025-04 to 2026-11-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05752136","detected":"2026-09-28","id":"trial-completion:nct05752136:yearreported-calendar:2026-11-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06005493","entityName":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","entityKind":"trial","route":"/trials/nct06005493/","file":"src/data/pipeline-trials-wave5.ts","line":3573,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3573","field":"yearReported / calendar","current":"2027-07-16","proposed":"2029-03-16","evidence":"Primary completion date moved from 2027-07-16 to 2029-03-16; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06005493","detected":"2026-09-28","id":"trial-completion:nct06005493:yearreported-calendar:2029-03-16"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06062420","entityName":"A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202","entityKind":"trial","route":"/trials/nct06062420/","file":"src/data/pipeline-trials-wave6.ts","line":419,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L419","field":"yearReported / calendar","current":"2026-09-01","proposed":"2026-09-10","evidence":"Primary completion date moved from 2026-09-01 to 2026-09-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06062420","detected":"2026-09-28","id":"trial-completion:nct06062420:yearreported-calendar:2026-09-10"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06109272","entityName":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)","entityKind":"trial","route":"/trials/nct06109272/","file":"src/data/pipeline-trials-wave2.ts","line":271,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave2.ts#L271","field":"yearReported / calendar","current":"2030-09","proposed":"2027-01","evidence":"Primary completion date moved from 2030-09 to 2027-01; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06109272","detected":"2026-09-28","id":"trial-completion:nct06109272:yearreported-calendar:2027-01"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06140836","entityName":"A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)","entityKind":"trial","route":"/trials/nct06140836/","file":"src/data/pipeline-trials-wave6.ts","line":9680,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L9680","field":"yearReported / calendar","current":"2026-03-13","proposed":"2027-02-16","evidence":"Primary completion date moved from 2026-03-13 to 2027-02-16; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06140836","detected":"2026-09-28","id":"trial-completion:nct06140836:yearreported-calendar:2027-02-16"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06151574","entityName":"Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment","entityKind":"trial","route":"/trials/nct06151574/","file":"src/data/pipeline-trials-wave6.ts","line":2842,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2842","field":"yearReported / calendar","current":"2026-09-02","proposed":"2026-12-10","evidence":"Primary completion date moved from 2026-09-02 to 2026-12-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06151574","detected":"2026-09-28","id":"trial-completion:nct06151574:yearreported-calendar:2026-12-10"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06564844","entityName":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following C","entityKind":"trial","route":"/trials/nct06564844/","file":"src/data/pipeline-trials-wave4.ts","line":730,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave4.ts#L730","field":"yearReported / calendar","current":"2027-06-30","proposed":"2026-07-10","evidence":"Primary completion date moved from 2027-06-30 to 2026-07-10; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06564844","detected":"2026-09-28","id":"trial-completion:nct06564844:yearreported-calendar:2026-07-10"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06601504","entityName":"Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL","entityKind":"trial","route":"/trials/nct06601504/","file":"src/data/pipeline-trials-wave5.ts","line":162,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L162","field":"yearReported / calendar","current":"2026-05-12","proposed":"2026-05-23","evidence":"Primary completion date moved from 2026-05-12 to 2026-05-23; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06601504","detected":"2026-09-28","id":"trial-completion:nct06601504:yearreported-calendar:2026-05-23"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06660654","entityName":"A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)","entityKind":"trial","route":"/trials/nct06660654/","file":"src/data/pipeline-trials-wave6.ts","line":7969,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7969","field":"yearReported / calendar","current":"2027-09-30","proposed":"2029-12-30","evidence":"Primary completion date moved from 2027-09-30 to 2029-12-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06660654","detected":"2026-09-28","id":"trial-completion:nct06660654:yearreported-calendar:2029-12-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06736717","entityName":"Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","entityKind":"trial","route":"/trials/nct06736717/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":861,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L861","field":"yearReported / calendar","current":"2026-07","proposed":"2026-07-16","evidence":"Primary completion date moved from 2026-07 to 2026-07-16; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06736717","detected":"2026-09-28","id":"trial-completion:nct06736717:yearreported-calendar:2026-07-16"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06989437","entityName":"A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue","entityKind":"trial","route":"/trials/nct06989437/","file":"src/data/pipeline-trials-wave6.ts","line":7933,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7933","field":"yearReported / calendar","current":"2028-01-17","proposed":"2028-01-23","evidence":"Primary completion date moved from 2028-01-17 to 2028-01-23; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06989437","detected":"2026-09-28","id":"trial-completion:nct06989437:yearreported-calendar:2028-01-23"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07069712","entityName":"A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma","entityKind":"trial","route":"/trials/nct07069712/","file":"src/data/pipeline-trials-wave6.ts","line":6072,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6072","field":"yearReported / calendar","current":"2027-11-03","proposed":"2027-11-09","evidence":"Primary completion date moved from 2027-11-03 to 2027-11-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07069712","detected":"2026-09-28","id":"trial-completion:nct07069712:yearreported-calendar:2027-11-09"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07405164","entityName":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","entityKind":"trial","route":"/trials/nct07405164/","file":"src/data/pipeline-trials-wave6.ts","line":7844,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L7844","field":"yearReported / calendar","current":"2034-01-14","proposed":"2034-04-22","evidence":"Primary completion date moved from 2034-01-14 to 2034-04-22; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07405164","detected":"2026-09-28","id":"trial-completion:nct07405164:yearreported-calendar:2034-04-22"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07419880","entityName":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","entityKind":"trial","route":"/trials/nct07419880/","file":"src/data/spikes/tnbc-registry-trials.ts","line":499,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/tnbc-registry-trials.ts#L499","field":"yearReported / calendar","current":"2027-01-30","proposed":"2027-12-31","evidence":"Primary completion date moved from 2027-01-30 to 2027-12-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07419880","detected":"2026-09-28","id":"trial-completion:nct07419880:yearreported-calendar:2027-12-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07619521","entityName":"Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma","entityKind":"trial","route":"/trials/nct07619521/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":1337,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L1337","field":"yearReported / calendar","current":"2026-10-30","proposed":"2028-09-08","evidence":"Primary completion date moved from 2026-10-30 to 2028-09-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07619521","detected":"2026-09-28","id":"trial-completion:nct07619521:yearreported-calendar:2028-09-08"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07769502","entityName":"A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatob","entityKind":"trial","route":"/trials/nct07769502/","file":"src/data/spikes/lung-trial-sponsors.ts","line":147,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-trial-sponsors.ts#L147","field":"yearReported / calendar","current":"2028-11","proposed":"2028-09","evidence":"Primary completion date moved from 2028-11 to 2028-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07769502","detected":"2026-09-28","id":"trial-completion:nct07769502:yearreported-calendar:2028-09"},{"kind":"trial-completion","confidence":"medium","entityId":"nct04771130","entityName":"A Study of BGB-11417 in Participants With Myeloid Malignancies","entityKind":"trial","route":"/trials/nct04771130/","file":"src/data/pipeline-trials-wave6.ts","line":2514,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L2514","field":"yearReported / calendar","current":"2028-02-08","proposed":"2028-08-31","evidence":"Primary completion date moved from 2028-02-08 to 2028-08-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT04771130","detected":"2026-09-17","id":"trial-completion:nct04771130:yearreported-calendar:2028-08-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05262400","entityName":"A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors","entityKind":"trial","route":"/trials/nct05262400/","file":"src/data/pipeline-trials-wave6.ts","line":6240,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6240","field":"yearReported / calendar","current":"2026-08-23","proposed":"2027-02-26","evidence":"Primary completion date moved from 2026-08-23 to 2027-02-26; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05262400","detected":"2026-09-17","id":"trial-completion:nct05262400:yearreported-calendar:2027-02-26"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05438459","entityName":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","entityKind":"trial","route":"/trials/nct05438459/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":746,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L746","field":"yearReported / calendar","current":"2028-12-31","proposed":"2032-03-31","evidence":"Primary completion date moved from 2028-12-31 to 2032-03-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05438459","detected":"2026-09-17","id":"trial-completion:nct05438459:yearreported-calendar:2032-03-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06065748","entityName":"A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)","entityKind":"trial","route":"/trials/nct06065748/","file":"src/data/pipeline-trials-wave6.ts","line":1247,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1247","field":"yearReported / calendar","current":"2027-02-19","proposed":"2028-04-20","evidence":"Primary completion date moved from 2027-02-19 to 2028-04-20; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06065748","detected":"2026-09-17","id":"trial-completion:nct06065748:yearreported-calendar:2028-04-20"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06297226","entityName":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","entityKind":"trial","route":"/trials/nct06297226/","file":"src/data/pipeline-trials-wave5.ts","line":2113,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L2113","field":"yearReported / calendar","current":"2027-06-30","proposed":"2026-07-31","evidence":"Primary completion date moved from 2027-06-30 to 2026-07-31; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06297226","detected":"2026-09-17","id":"trial-completion:nct06297226:yearreported-calendar:2026-07-31"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06423911","entityName":"Study of Olverembatinib (HQP1351) in Patients With CML-CP","entityKind":"trial","route":"/trials/nct06423911/","file":"src/data/pipeline-trials-wave3.ts","line":12,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave3.ts#L12","field":"yearReported / calendar","current":"2025-12","proposed":"2027-06-30","evidence":"Primary completion date moved from 2025-12 to 2027-06-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06423911","detected":"2026-09-17","id":"trial-completion:nct06423911:yearreported-calendar:2027-06-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06901531","entityName":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","entityKind":"trial","route":"/trials/nct06901531/","file":"src/data/pipeline-trials-wave6.ts","line":1783,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L1783","field":"yearReported / calendar","current":"2027-03-31","proposed":"2028-09-30","evidence":"Primary completion date moved from 2027-03-31 to 2028-09-30; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06901531","detected":"2026-09-17","id":"trial-completion:nct06901531:yearreported-calendar:2028-09-30"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07332000","entityName":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","entityKind":"trial","route":"/trials/nct07332000/","file":"src/data/pipeline-trials-wave5.ts","line":354,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L354","field":"yearReported / calendar","current":"2026-08","proposed":"2027-02","evidence":"Primary completion date moved from 2026-08 to 2027-02; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07332000","detected":"2026-09-17","id":"trial-completion:nct07332000:yearreported-calendar:2027-02"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07367516","entityName":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","entityKind":"trial","route":"/trials/nct07367516/","file":"src/data/pipeline-trials-wave6.ts","line":6186,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L6186","field":"yearReported / calendar","current":"2026-09","proposed":"2027-02","evidence":"Primary completion date moved from 2026-09 to 2027-02; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07367516","detected":"2026-09-17","id":"trial-completion:nct07367516:yearreported-calendar:2027-02"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07551596","entityName":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","entityKind":"trial","route":"/trials/nct07551596/","file":"src/data/spikes/colorectal-registry-trials.ts","line":2355,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L2355","field":"yearReported / calendar","current":"2026-09-30","proposed":"2029-08-28","evidence":"Primary completion date moved from 2026-09-30 to 2029-08-28; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07551596","detected":"2026-09-17","id":"trial-completion:nct07551596:yearreported-calendar:2029-08-28"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07581002","entityName":"A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)","entityKind":"trial","route":"/trials/nct07581002/","file":"src/data/pipeline-trials-wave6.ts","line":5928,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave6.ts#L5928","field":"yearReported / calendar","current":"2032-05","proposed":"2032-06","evidence":"Primary completion date moved from 2032-05 to 2032-06; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07581002","detected":"2026-09-17","id":"trial-completion:nct07581002:yearreported-calendar:2032-06"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05186974","entityName":"Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)","entityKind":"trial","route":"/trials/nct05186974/","file":"src/data/pipeline-trials-wave5.ts","line":3645,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L3645","field":"yearReported / calendar","current":"2026-09","proposed":"2027-03","evidence":"Primary completion date moved from 2026-09 to 2027-03; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05186974","detected":"2026-09-11","id":"trial-completion:nct05186974:yearreported-calendar:2027-03"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05201248","entityName":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th","entityKind":"trial","route":"/trials/nct05201248/","file":"src/data/pipeline-trials-wave5.ts","line":1725,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/pipeline-trials-wave5.ts#L1725","field":"yearReported / calendar","current":"2025-04","proposed":"2026-09","evidence":"Primary completion date moved from 2025-04 to 2026-09; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05201248","detected":"2026-09-11","id":"trial-completion:nct05201248:yearreported-calendar:2026-09"},{"kind":"trial-completion","confidence":"medium","entityId":"nct05845450","entityName":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","entityKind":"trial","route":"/trials/nct05845450/","file":"src/data/spikes/colorectal-registry-trials.ts","line":1014,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L1014","field":"yearReported / calendar","current":"2026-05","proposed":"2027-05","evidence":"Primary completion date moved from 2026-05 to 2027-05; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT05845450","detected":"2026-09-11","id":"trial-completion:nct05845450:yearreported-calendar:2027-05"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07602855","entityName":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","entityKind":"trial","route":"/trials/nct07602855/","file":"src/data/spikes/lung-registry-trials.ts","line":1574,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L1574","field":"yearReported / calendar","current":"2029-07-05","proposed":"2029-06-21","evidence":"Primary completion date moved from 2029-07-05 to 2029-06-21; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07602855","detected":"2026-09-10","id":"trial-completion:nct07602855:yearreported-calendar:2029-06-21"},{"kind":"trial-completion","confidence":"medium","entityId":"nct07016230","entityName":"Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocri","entityKind":"trial","route":"/trials/nct07016230/","file":"src/data/spikes/lung-registry-trials.ts","line":1748,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L1748","field":"yearReported / calendar","current":"2026-10-18","proposed":"2027-05-18","evidence":"Primary completion date moved from 2026-10-18 to 2027-05-18; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT07016230","detected":"2026-09-09","id":"trial-completion:nct07016230:yearreported-calendar:2027-05-18"},{"kind":"trial-status","confidence":"low","entityId":"alkove-1","entityName":"ALKOVE-1","entityKind":"trial","route":"/trials/alkove-1/","file":"src/data/spikes/nsclc.ts","line":120,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/nsclc.ts#L120","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT05384626","id":"trial-status:alkove-1:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"a071401","entityName":"Alliance A071401","entityKind":"trial","route":"/trials/a071401/","file":"src/data/issues-2026-09-wave-b.ts","line":239,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/issues-2026-09-wave-b.ts#L239","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT02523014","id":"trial-status:a071401:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"augment-101","entityName":"AUGMENT-101","entityKind":"trial","route":"/trials/augment-101/","file":"src/data/spikes/aml.ts","line":329,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/aml.ts#L329","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT04065399","id":"trial-status:augment-101:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"firefly-1","entityName":"FIREFLY-1","entityKind":"trial","route":"/trials/firefly-1/","file":"src/data/paediatric-fronts.ts","line":31,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/paediatric-fronts.ts#L31","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT04775485","id":"trial-status:firefly-1:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"linker-mm1","entityName":"LINKER-MM1","entityKind":"trial","route":"/trials/linker-mm1/","file":"src/data/spikes/multiple-myeloma.ts","line":226,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/multiple-myeloma.ts#L226","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03761108","id":"trial-status:linker-mm1:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"monumental-1","entityName":"MonumenTAL-1","entityKind":"trial","route":"/trials/monumental-1/","file":"src/data/spikes/multiple-myeloma.ts","line":219,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/multiple-myeloma.ts#L219","field":"status","current":"positive","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded positive. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT04634552","id":"trial-status:monumental-1:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"nct07472868","entityName":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk","entityKind":"trial","route":"/trials/nct07472868/","file":"src/data/spikes/colorectal-registry-trials.ts","line":3731,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L3731","field":"status","current":"planned","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded planned. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07472868","id":"trial-status:nct07472868:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"nct07808151","entityName":"Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer","entityKind":"trial","route":"/trials/nct07808151/","file":"src/data/spikes/colorectal-registry-trials.ts","line":383,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/colorectal-registry-trials.ts#L383","field":"status","current":"planned","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded planned. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07808151","id":"trial-status:nct07808151:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"nct07162883","entityName":"Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)","entityKind":"trial","route":"/trials/nct07162883/","file":"src/data/spikes/lung-registry-trials.ts","line":541,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L541","field":"status","current":"planned","proposed":"active","evidence":"ClinicalTrials.gov overall status is ACTIVE_NOT_RECRUITING; recorded planned. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07162883","id":"trial-status:nct07162883:status:active","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"nct07416058","entityName":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","entityKind":"trial","route":"/trials/nct07416058/","file":"src/data/spikes/lung-registry-trials.ts","line":433,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/lung-registry-trials.ts#L433","field":"status","current":"planned","proposed":"recruiting","evidence":"ClinicalTrials.gov overall status is RECRUITING; recorded planned. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07416058","id":"trial-status:nct07416058:status:recruiting","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"nct04172532","entityName":"Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer","entityKind":"trial","route":"/trials/nct04172532/","file":"src/data/spikes/pancreatic-registry-trials.ts","line":740,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/pancreatic-registry-trials.ts#L740","field":"status","current":"recruiting","proposed":"mixed","evidence":"ClinicalTrials.gov overall status is SUSPENDED; recorded recruiting. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT04172532","id":"trial-status:nct04172532:status:mixed","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"nct07146646","entityName":"Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer","entityKind":"trial","route":"/trials/nct07146646/","file":"src/data/spikes/gallbladder-registry-trials.ts","line":441,"editUrl":"https://github.com/judegomila/OnCo/blob/main/src/data/spikes/gallbladder-registry-trials.ts#L441","field":"status","current":"recruiting","proposed":"mixed","evidence":"ClinicalTrials.gov overall status is SUSPENDED; recorded recruiting. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT07146646","id":"trial-status:nct07146646:status:mixed","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Nezglyal","field":"new drug record","current":"(not in corpus)","proposed":"add product leriglitazone (Nezglyal) with the EU status the register page shows","evidence":"EMA register: Nezglyal (leriglitazone) Authorised, 2026-09-21. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2026-09-21, opinion Positive 2026-07-23.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/nezglyal","reason":"no corpus product is named exactly leriglitazone / leriglitazone / Nezglyal","id":"new-product:nezglyal:new-drug-record:add-product-leriglitazone-nezglyal-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Waskyra","field":"new drug record","current":"(not in corpus)","proposed":"add product etuvetidigene autotemcel (Waskyra) with the EU status the register page shows","evidence":"EMA register: Waskyra (etuvetidigene autotemcel) Authorised, 2026-01-09. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2026-01-09.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/waskyra","reason":"no corpus product is named exactly etuvetidigene autotemcel / genetically modified autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human Wiskott-Aldrich Syndrome (WAS) gene / Waskyra","id":"new-product:waskyra:new-drug-record:add-product-etuvetidigene-autotemcel-waskyra-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Lynkuet","field":"new drug record","current":"(not in corpus)","proposed":"add product elinzanetant (Lynkuet) with the EU status the register page shows","evidence":"EMA register: Lynkuet (elinzanetant) Authorised, 2025-11-17. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2025-11-17.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/lynkuet","reason":"no corpus product is named exactly elinzanetant / elinzanetant / Lynkuet","id":"new-product:lynkuet:new-drug-record:add-product-elinzanetant-lynkuet-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Casgevy","field":"new drug record","current":"(not in corpus)","proposed":"add product exagamglogene autotemcel (Casgevy) with the EU status the register page shows","evidence":"EMA register: Casgevy (exagamglogene autotemcel) Authorised, 2024-02-09. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2024-02-09.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/casgevy","reason":"no corpus product is named exactly exagamglogene autotemcel / Exagamglogene autotemcel / Casgevy","id":"new-product:casgevy:new-drug-record:add-product-exagamglogene-autotemcel-casgevy-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Libmeldy","field":"new drug record","current":"(not in corpus)","proposed":"add product autologous CD34+ cells encoding ARSA gene (Libmeldy) with the EU status the register page shows","evidence":"EMA register: Libmeldy (autologous CD34+ cells encoding ARSA gene) Authorised, 2020-12-17. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2020-12-17.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/libmeldy","reason":"no corpus product is named exactly autologous CD34+ cells encoding ARSA gene / atidarsagene autotemcel / Libmeldy","id":"new-product:libmeldy:new-drug-record:add-product-autologous-cd34-cells-encoding-arsa-gene-libmeldy-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Lumeblue (previously Methylthioninium chloride Cosmo)","field":"new drug record","current":"(not in corpus)","proposed":"add product methylthioninium chloride (Lumeblue (previously Methylthioninium chloride Cosmo)) with the EU status the register page shows","evidence":"EMA register: Lumeblue (previously Methylthioninium chloride Cosmo) (methylthioninium chloride) Authorised, 2020-08-19. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2020-08-19.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/lumeblue","reason":"no corpus product is named exactly methylthioninium chloride / methylthioninium chloride / Lumeblue (previously Methylthioninium chloride Cosmo)","id":"new-product:lumeblue-previously-methylthioninium-chloride-cosmo-:new-drug-record:add-product-methylthioninium-chloride-lumeblue-previously-methylthioninium-chlo","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Xromi","field":"new drug record","current":"(not in corpus)","proposed":"add product hydroxycarbamide (Xromi) with the EU status the register page shows","evidence":"EMA register: Xromi (hydroxycarbamide) Authorised, 2019-07-01. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2019-07-01.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/xromi","reason":"no corpus product is named exactly hydroxycarbamide / hydroxycarbamide / Xromi","id":"new-product:xromi:new-drug-record:add-product-hydroxycarbamide-xromi-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"SomaKit TOC","field":"new drug record","current":"(not in corpus)","proposed":"add product edotreotide (SomaKit TOC) with the EU status the register page shows","evidence":"EMA register: SomaKit TOC (edotreotide) Authorised, 2016-12-08. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2016-12-08.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc","reason":"no corpus product is named exactly edotreotide / edotreotide / SomaKit TOC","id":"new-product:somakit-toc:new-drug-record:add-product-edotreotide-somakit-toc-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Strimvelis","field":"new drug record","current":"(not in corpus)","proposed":"add product autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence (Strimvelis) with the EU status the register page shows","evidence":"EMA register: Strimvelis (autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) Authorised, 2016-05-26. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2016-05-26.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/strimvelis","reason":"no corpus product is named exactly autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence / autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells / Strimvelis","id":"new-product:strimvelis:new-drug-record:add-product-autologous-cd34-enriched-cell-fraction-that-contains-cd34-cells-transduced-with-retroviral-vector-that-encode","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Entyvio","field":"new drug record","current":"(not in corpus)","proposed":"add product vedolizumab (Entyvio) with the EU status the register page shows","evidence":"EMA register: Entyvio (vedolizumab) Authorised, 2014-05-22. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2014-05-22.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio","reason":"no corpus product is named exactly vedolizumab / vedolizumab / Entyvio","id":"new-product:entyvio:new-drug-record:add-product-vedolizumab-entyvio-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Procysbi","field":"new drug record","current":"(not in corpus)","proposed":"add product mercaptamine (Procysbi) with the EU status the register page shows","evidence":"EMA register: Procysbi (mercaptamine) Authorised, 2013-09-05. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 2013-09-05.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/procysbi","reason":"no corpus product is named exactly mercaptamine / mercaptamine bitartrate / Procysbi","id":"new-product:procysbi:new-drug-record:add-product-mercaptamine-procysbi-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"NeoRecormon","field":"new drug record","current":"(not in corpus)","proposed":"add product epoetin beta (NeoRecormon) with the EU status the register page shows","evidence":"EMA register: NeoRecormon (epoetin beta) Authorised, 1997-07-16. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 1997-07-16.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon","reason":"no corpus product is named exactly epoetin beta / epoetin beta / NeoRecormon","id":"new-product:neorecormon:new-drug-record:add-product-epoetin-beta-neorecormon-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Cystagon","field":"new drug record","current":"(not in corpus)","proposed":"add product mercaptamine bitartrate (Cystagon) with the EU status the register page shows","evidence":"EMA register: Cystagon (mercaptamine bitartrate) Authorised, 1997-06-23. Register page: \"Authorised: This medicine is authorised for use in the European Union\", authorised 1997-06-23.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/cystagon","reason":"no corpus product is named exactly mercaptamine bitartrate / mercaptamine bitartrate / Cystagon","id":"new-product:cystagon:new-drug-record:add-product-mercaptamine-bitartrate-cystagon-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Yartemlea","field":"new drug record","current":"(not in corpus)","proposed":"add product Narsoplimab (Yartemlea) with the EU status the register page shows","evidence":"EMA register: Yartemlea (Narsoplimab) Opinion. Register page: \"Opinion: EMA has issued an opinion on this medicine\", opinion Negative 2026-10-15.","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/yartemlea","reason":"no corpus product is named exactly Narsoplimab / Yartemlea","id":"new-product:yartemlea:new-drug-record:add-product-narsoplimab-yartemlea-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"new-product","confidence":"low","entityName":"Zefylti","field":"new drug record","current":"(not in corpus)","proposed":"add product filgrastim (Zefylti) with the EU status the register page shows","evidence":"EMA register: Zefylti (filgrastim) Application withdrawn. Register page: \"Application withdrawn: The application for this medicine has been withdrawn\".","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/zefylti-0","reason":"no corpus product is named exactly filgrastim / filgrastim / Zefylti (the snapshot's nearest name was filgrastim, a partial match)","id":"new-product:zefylti:new-drug-record:add-product-filgrastim-zefylti-with-the-eu-status-the-register-page-shows","detected":"2026-10-30"},{"kind":"trial-status","confidence":"low","entityId":"denosumab","entityName":"Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks (NCT02051218)","entityKind":"trial","route":"/drugs/denosumab/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT02051218 for Denosumab with status withdrawn","evidence":"A phase 3 study of Denosumab moved from ACTIVE_NOT_RECRUITING to TERMINATED (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT02051218","detected":"2026-10-26","id":"trial-status:denosumab:new-trial-record:add-phase-3-trial-nct02051218-for-denosumab-with-status-withdrawn"},{"kind":"trial-status","confidence":"low","entityId":"eltrombopag","entityName":"Decitabine for Poor Graft Function Post Allo-HSCT (NCT05907499)","entityKind":"trial","route":"/drugs/eltrombopag/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT05907499 for Eltrombopag with status completed","evidence":"A phase 3 study of Eltrombopag moved from NOT_YET_RECRUITING to COMPLETED (detected 2026-10-26).","sourceUrl":"https://clinicaltrials.gov/study/NCT05907499","detected":"2026-10-26","id":"trial-status:eltrombopag:new-trial-record:add-phase-3-trial-nct05907499-for-eltrombopag-with-status-completed"},{"kind":"trial-status","confidence":"low","entityId":"alpelisib","entityName":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET) (NCT05063786)","entityKind":"trial","route":"/drugs/alpelisib/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT05063786 for Alpelisib with status withdrawn","evidence":"A phase 3 study of Alpelisib moved from ACTIVE_NOT_RECRUITING to TERMINATED (detected 2026-10-19).","sourceUrl":"https://clinicaltrials.gov/study/NCT05063786","detected":"2026-10-19","id":"trial-status:alpelisib:new-trial-record:add-phase-3-trial-nct05063786-for-alpelisib-with-status-withdrawn"},{"kind":"trial-status","confidence":"low","entityId":"diazoxide","entityName":"Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome (NCT05701774)","entityKind":"trial","route":"/drugs/diazoxide/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT05701774 for Diazoxide with status completed","evidence":"A phase 3 study of Diazoxide moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-10-19).","sourceUrl":"https://clinicaltrials.gov/study/NCT05701774","detected":"2026-10-19","id":"trial-status:diazoxide:new-trial-record:add-phase-3-trial-nct05701774-for-diazoxide-with-status-completed"},{"kind":"trial-status","confidence":"low","entityId":"fludeoxyglucose-f18","entityName":"Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis (NCT02824419)","entityKind":"trial","route":"/drugs/fludeoxyglucose-f18/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT02824419 for Fludeoxyglucose F-18 (FDG) with status withdrawn","evidence":"A phase 3 study of Fludeoxyglucose F-18 (FDG) moved from UNKNOWN to TERMINATED (detected 2026-10-12).","sourceUrl":"https://clinicaltrials.gov/study/NCT02824419","detected":"2026-10-12","id":"trial-status:fludeoxyglucose-f18:new-trial-record:add-phase-3-trial-nct02824419-for-fludeoxyglucose-f-18-fdg-with-status-withdrawn"},{"kind":"trial-status","confidence":"low","entityId":"dronabinol","entityName":"Reducing Breathlessness With Dronabinol in COPD Patients (NCT06473701)","entityKind":"trial","route":"/drugs/dronabinol/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT06473701 for Dronabinol with status completed","evidence":"A phase 3 study of Dronabinol moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-10-12).","sourceUrl":"https://clinicaltrials.gov/study/NCT06473701","detected":"2026-10-12","id":"trial-status:dronabinol:new-trial-record:add-phase-3-trial-nct06473701-for-dronabinol-with-status-completed"},{"kind":"trial-status","confidence":"low","entityId":"mebendazole","entityName":"Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections (NCT06736691)","entityKind":"trial","route":"/drugs/mebendazole/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT06736691 for Mebendazole with status completed","evidence":"A phase 3 study of Mebendazole moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-10-12).","sourceUrl":"https://clinicaltrials.gov/study/NCT06736691","detected":"2026-10-12","id":"trial-status:mebendazole:new-trial-record:add-phase-3-trial-nct06736691-for-mebendazole-with-status-completed"},{"kind":"trial-status","confidence":"low","entityId":"tiragolumab","entityName":"A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (NCT04543617)","entityKind":"trial","route":"/drugs/tiragolumab/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT04543617 for Tiragolumab with status completed","evidence":"A phase 3 study of Tiragolumab moved from ACTIVE_NOT_RECRUITING to COMPLETED (detected 2026-09-17).","sourceUrl":"https://clinicaltrials.gov/study/NCT04543617","detected":"2026-09-17","id":"trial-status:tiragolumab:new-trial-record:add-phase-3-trial-nct04543617-for-tiragolumab-with-status-completed"}],"auto":{"rows":[],"alreadyOnMain":0}}